XSTO
GABA
Market cap833kUSD
Apr 11, Last price
0.04SEK
1D
-6.88%
1Q
-93.82%
Jan 2017
-99.92%
IPO
-99.81%
Name
Gabather AB
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
22.89%
Rev. gr., 5y
-52.95%
Revenues
0k
Net income
-8m
L-17.84%
CFO
-3m
L-71.42%
Profile
Gabather AB (publ) develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company was incorporated in 2014 and is based in Södertälje Sweden.
Valuation
Title SEK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | 4,518 | |||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | (4,518) | |||||||||
NOPBT Margin | ||||||||||
Operating Taxes | (3) | |||||||||
Tax Rate | ||||||||||
NOPAT | (4,515) | |||||||||
Net income | (7,753) -17.84% | (9,437) 10.44% | (8,545) -49.73% | |||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | 4,409 | 8,466 | 1,022 | |||||||
BB yield | -53.31% | -41.55% | -1.66% | |||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | 183 | |||||||||
Net debt | (878) | (1,165) | (6,322) | |||||||
| Cash flow | ||||||||||
Cash from operating activities | (3,328) | (11,643) | (9,597) | |||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | 3,091 | 6,486 | 1,022 | |||||||
FCF | 234 | 3,991 | (4,515) | |||||||
| Balance | ||||||||||
Cash | 878 | 1,115 | 6,272 | |||||||
Long term investments | 50 | 50 | ||||||||
Excess cash | 878 | 1,165 | 6,322 | |||||||
Stockholders' equity | (119,410) | (113,826) | (104,861) | |||||||
Invested Capital | 115,235 | 114,312 | 108,299 | |||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | 20,676 | 14,451 | 13,604 | |||||||
Price | 0.40 -71.63% | 1.41 -68.87% | 4.53 0.00% | |||||||
Market cap | 8,271 -59.41% | 20,376 -66.94% | 61,627 1.47% | |||||||
EV | 7,393 | 19,211 | 55,305 | |||||||
EBITDA | (4,518) | |||||||||
EV/EBITDA | ||||||||||
Interest | 3 | |||||||||
Interest/NOPBT | ||||||||||